HK1092141A1 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors

Info

Publication number
HK1092141A1
HK1092141A1 HK06112572.5A HK06112572A HK1092141A1 HK 1092141 A1 HK1092141 A1 HK 1092141A1 HK 06112572 A HK06112572 A HK 06112572A HK 1092141 A1 HK1092141 A1 HK 1092141A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
HK06112572.5A
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1092141A1 publication Critical patent/HK1092141A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Lubricants (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK06112572.5A 2003-09-13 2006-11-15 Matrix metalloproteinase inhibitors HK1092141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HK1092141A1 true HK1092141A1 (en) 2007-02-02

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06112572.5A HK1092141A1 (en) 2003-09-13 2006-11-15 Matrix metalloproteinase inhibitors

Country Status (29)

Country Link
US (3) US7601729B2 (pt)
EP (3) EP2295408A1 (pt)
JP (3) JP2007505081A (pt)
KR (3) KR20120007566A (pt)
CN (1) CN1849306B (pt)
AT (2) ATE502922T1 (pt)
AU (1) AU2004272280C1 (pt)
BR (1) BRPI0413791A (pt)
CA (1) CA2538315C (pt)
CY (1) CY1109400T1 (pt)
DE (2) DE602004031991D1 (pt)
DK (1) DK1663970T3 (pt)
ES (2) ES2362954T3 (pt)
GB (1) GB0321538D0 (pt)
HK (1) HK1092141A1 (pt)
HR (1) HRP20080668T3 (pt)
IL (1) IL173305A (pt)
IS (2) IS2622B (pt)
MA (1) MA28039A1 (pt)
MX (1) MXPA06002458A (pt)
NO (1) NO20060540L (pt)
NZ (2) NZ573479A (pt)
PL (1) PL1663970T3 (pt)
PT (1) PT1663970E (pt)
RU (2) RU2370488C2 (pt)
SG (1) SG145685A1 (pt)
SI (1) SI1663970T1 (pt)
WO (1) WO2005026120A1 (pt)
ZA (1) ZA200602070B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1856063B1 (en) * 2005-02-22 2012-01-25 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
ES2397284T3 (es) 2006-08-22 2013-03-06 Ranbaxy Laboratories Limited Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
CN103228634A (zh) 2010-09-24 2013-07-31 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
EP2926808A1 (en) 2012-11-28 2015-10-07 Administración General De La Communidad Autónoma De Euskadi Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
AR107592A1 (es) 2016-02-12 2018-05-16 Astellas Pharma Inc Derivados de tetrahidroisoquinolina
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
EE9800172A (et) * 1995-12-06 1998-12-15 Astra Pharmaceuticals Limited Ühendid
AU725847B2 (en) 1996-04-19 2000-10-19 Merck Sharp & Dohme B.V. Substituted benzylamines and their use for the treatment of depression
ZA974032B (en) * 1996-05-15 1998-02-19 Bayer Ag Substituted oxobutyric acids as matrix metalloproteinases inhibitors.
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
MXPA03009361A (es) * 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
AU2003261319A1 (en) * 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
ATE455096T1 (de) * 2002-11-19 2010-01-15 Galderma Res & Dev Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1856063B1 (en) 2005-02-22 2012-01-25 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
ES2397284T3 (es) 2006-08-22 2013-03-06 Ranbaxy Laboratories Limited Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos

Also Published As

Publication number Publication date
RU2008146479A (ru) 2010-06-20
KR20060120648A (ko) 2006-11-27
US20060293353A1 (en) 2006-12-28
CA2538315A1 (en) 2005-03-24
IL173305A (en) 2011-01-31
ES2362954T3 (es) 2011-07-15
DE602004017622D1 (de) 2008-12-18
MA28039A1 (fr) 2006-07-03
EP2295408A1 (en) 2011-03-16
IS8268A (is) 2006-01-26
JP2011231118A (ja) 2011-11-17
DK1663970T3 (da) 2009-01-12
GB0321538D0 (en) 2003-10-15
PT1663970E (pt) 2009-01-09
US20100029699A1 (en) 2010-02-04
EP1663970B1 (en) 2008-11-05
AU2004272280A1 (en) 2005-03-24
IS2622B (is) 2010-05-15
JP2007505081A (ja) 2007-03-08
US8263602B2 (en) 2012-09-11
US8343986B2 (en) 2013-01-01
MXPA06002458A (es) 2006-06-20
RU2370488C2 (ru) 2009-10-20
EP1663970A1 (en) 2006-06-07
ZA200602070B (en) 2007-05-30
ES2314436T3 (es) 2009-03-16
US7601729B2 (en) 2009-10-13
KR20130079628A (ko) 2013-07-10
IS8843A (is) 2009-08-19
ATE502922T1 (de) 2011-04-15
IL173305A0 (en) 2006-06-11
ATE413384T1 (de) 2008-11-15
BRPI0413791A (pt) 2006-11-07
KR20120007566A (ko) 2012-01-20
AU2004272280B2 (en) 2011-04-21
PL1663970T3 (pl) 2009-04-30
JP2012107031A (ja) 2012-06-07
CN1849306B (zh) 2014-01-29
CN1849306A (zh) 2006-10-18
SI1663970T1 (sl) 2009-04-30
SG145685A1 (en) 2008-09-29
WO2005026120A1 (en) 2005-03-24
NO20060540L (no) 2006-04-04
EP2042488A1 (en) 2009-04-01
CY1109400T1 (el) 2014-07-02
NZ545211A (en) 2009-01-31
CA2538315C (en) 2014-04-08
HRP20080668T3 (en) 2009-02-28
EP2042488B1 (en) 2011-03-23
AU2004272280C1 (en) 2011-10-27
NZ573479A (en) 2010-09-30
US20090082377A1 (en) 2009-03-26
DE602004031991D1 (de) 2011-05-05
RU2006106850A (ru) 2007-10-20

Similar Documents

Publication Publication Date Title
HRP20080668T3 (en) Matrix metalloproteinase inhibitors
ATE362910T1 (de) Matrix metalloprotease inhibitoren
IL154893A0 (en) Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
DE3883140D1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
YU74201A (sh) Nova sinteza prstena piperazina
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2002074764A3 (en) Piperazine derivatives and their use as 5-ht1b ligands
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
GB1183442A (pt)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150910